fig4

Figure 4. LINC01133 attenuates cisplatin cytotoxicity by suppressing the Caspase-1/GSDMD pyroptosis pathway. (A) Morphological changes in A549 and A549/DDP cells following cisplatin administration were measured by TEM. Scale bar: 5 μm; (B) The proportion of late apoptotic/necrotic cells after cisplatin administration was identified by Annexin V-FITC/PI double staining; (C) Changes in the protein levels of Caspase-1, cleaved Caspase-1, GSDMD, and GSDMD-NT in cells before and after cisplatin treatment were measured by Western blotting. Data were obtained from three independent biological replicates and are presented as the mean ± SD (n = 3). Densitometric values of the target proteins were normalized to GAPDH and are presented as relative protein expression levels; (D) Role of LINC01133 expression in key pyroptosis markers, as measured by Western blotting. Data were obtained from three independent biological replicates and are presented as the mean ± SD (n = 3). Densitometric values of the target proteins were normalized to GAPDH and are presented as relative protein expression levels; (E) Effect of LINC01133 expression on the levels of the inflammatory cytokines IL-1β and IL-18 in cell supernatants measured via ELISA; (F) Effect of LINC01133 expression on cell membrane leakage, as assessed by LDH release assays. Comparisons among multiple group means were performed by one-way ANOVA. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001. DDP: Cisplatin; TEM: transmission electron microscopy; SD: standard deviation; ELISA: enzyme-linked immunosorbent assay; LDH: lactate dehydrogenase; ANOVA: analysis of variance.